La Fundació PCB Page

Portal de Transparència Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure...

A pioneering study conducted by Eugin reveals that women with Covid-19 produce virus-free eggs Blog Post

A study carried out by a team of researchers from Eugin’s Basic Research Laboratory, headquartered in the Barcelona Science Park, published in the  journal Human Reproduction, has, for the first time, analysed the eggs of women diagnosed with Covid-19 detecting no viral material within them. The findings, globally considered ground-breaking and pioneering in the field of assisted reproduction, supports the notion that there would be no vertical transmission of the infection from mother to child via their eggs.

 

Kumux launches a 2.0 software which creates differential light to improve human health and plant growth Blog Post

A spin-off by the University of Barcelona Enlighting Technologies, based in the Barcelona Science Park, has created Kumux to launch a 2.0 simulation spectrum software which, through patented algorithms, creates a differential light with beneficial effects for health for both people and plant growth. It is an smart lighting solution –autonomous and based on LED technology–, compatible with different systems and designed so that it can be integrated into any luminaire or control platform.

 

Launch of the company Gate2Brain, based on novel technology developed at IRB Barcelona to transport drugs into the brain Blog Post

The Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona (UB) and the Sant Joan de Déu Research Institute (IRSJD)- Hospital Sant Joan de Déu (SJD) have set up Gate2Brain, a company based on a novel technology to transport drugs into the brain. The biotech, based in the Barcelona Science Park, is the second joint spin-off between IRB Barcelona and the UB to be funded by the Mind the Gap Programme run by the Botín Foundation.

 

Eugin presents pioneering advances in fertility and human reproduction at ESHRE 2020 Blog Post

An analysis of the environment in which the embryos that become implanted in the uterus develop reveals a lower number of senescent (aged) cells than those that are not successful. This is the result of a study presented yesterday at ESHRE 2020, which has been led by researchers from Eugin’s Basic Research Laboratory, headquartered in the Barcelona Science Park. The group also submited at the congress another work –carried out with the Center for Genomic Regulation (CRG) and the collaboration of the National Center for Genomic Analysis (CNAG)– which reveals that the quality of the eggs can lie in the networks that create their genes.

 

Vesismin introduces the Ultraviolet Germicidal Irradiation in leading hospitals Blog Post

The company Vesismin Health –present in the Barcelona Science Park and specialized in the development and commercialization of products for the control of infections in hospital environments– has introduced the advanced UVGI technology (Ultraviolet Germicidal Irradiation), in different hospitals in Spain. Its professional system for medical use, UV-360, produces germicidal ultraviolet radiation for comprehensive disinfection of rooms and is equipped with motion sensors that automatically interrupt operation when they detect a presence.

 

Ona Therapeutics raises €30M in Series A financing Blog Post

Ona Therapeutics –a spin-off from IRB Barcelona and ICREA, based in the Barcelona Science Park– announces today the closing of a €30 million Series A financing, the largest private funding round closed for a start-up in Spain. The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.

 

Gorka Etxebarria, new Chief Scientific Officer of Nostrum Biodiscovery Blog Post

Nostrum Biodiscovery (NBD) has appointed Dr. Gorka Etxebarria as new Chief Scientific Officer. Dr Etxebarria has a solid career linked to drug discovery projects in the pharmaceutical industry. His incorporation comes after the signing of Ezequiel Mas as new company CEO, to pilot a new stage of growth as a global provider of leading molecular simulation technologies applied to drug discovery and design.